Brief: Medivir To End Study With Birinapant, Keytruda In Colorectal Cancer Patients

Medivir AB

16/12/2019 15:05

Dec 16 (Reuters) - Medivir AB  MVIRb.ST :
    * FUTILITY ANALYSIS PERFORMED OF THE PHASE II COMBINATION STUDY WITH BIRINAPANT AND
KEYTRUDA® IN
COLORECTAL CANCER PATIENTS
    * PRIMARY OBJECTIVE OF PHASE II STUDY WAS AN IMPROVED CLINICAL RESPONSE TO TREATMENT
MEASURED AS
20% ORR (OVERALL RESPONSE RATE)
    * INDEPENDENT SAFETY COMMITTEE RECOMMENDATION IS THAT STUDY SHOULD BE TERMINATED
    * INDEPENDENT SAFETY COMMITTEE ANALYSIS INDICATES THAT IT IS UNLIKELY THAT STUDY'S
OBJECTIVES WILL
BE MET
    * CO DECIDED TO DISCONTINUE RECRUITMENT OF PATIENTS AND TO END STUDY

Source text for Eikon:  ID:nWkr30NyrR 
Further company coverage:  MVIRb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))